FDA Attempting to Address Unmet Needs for Patients with Brain Metastases
Molly Fellin Spence of Clarivate discusses the FDA’s efforts towards advancing the development of products for CNS metastases, where effective…
Molly Fellin Spence of Clarivate discusses the FDA’s efforts towards advancing the development of products for CNS metastases, where effective…
Drug discovery and development, while usually a role of the pharmaceutical industry, is a long, difficult and expensive process, which…
Adam Istas, DIA explores how global regulators are responding to dramatic increases in cell and gene-based products in development. Regulators…
LOINC is an internationally recognized classification system and is often requested in regulatory data submissions to provide context to clinical…
The FDA has been promoting innovative and disruptive approaches towards modernizing drug development and clinical trials, which the industry has…
Dr Balamuralidhara V. et al of the JSS College of Pharmacy present a study which examines the clinical evaluation and…
Orphan drug discovery presents both opportunities and challenges, with research in this space having some of the highest hurdles in…
Eye health and vision has a major impact on the quality of life, and as such the development of products…
Adult onset Still’s disease (AOSD) is a rare inflammatory joint disease of unknown aetiology, characterised by arthritis, fevers spiking once…
With 7,000 rare diseases affecting 350 million people worldwide, Holly Jackson at Quanticate identifies how businesses exploring rare diseases can…